WO2003074485A2 - Indole-amide derivatives and their use as glycogen phosphorylase inhibitors - Google Patents

Indole-amide derivatives and their use as glycogen phosphorylase inhibitors Download PDF

Info

Publication number
WO2003074485A2
WO2003074485A2 PCT/GB2003/000936 GB0300936W WO03074485A2 WO 2003074485 A2 WO2003074485 A2 WO 2003074485A2 GB 0300936 W GB0300936 W GB 0300936W WO 03074485 A2 WO03074485 A2 WO 03074485A2
Authority
WO
WIPO (PCT)
Prior art keywords
formula
group
compound
acceptable salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2003/000936
Other languages
French (fr)
Other versions
WO2003074485A3 (en
Inventor
Andrew David Morley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
AstraZeneca AB
Original Assignee
AstraZeneca UK Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca UK Ltd, AstraZeneca AB filed Critical AstraZeneca UK Ltd
Priority to US10/506,592 priority Critical patent/US7115648B2/en
Priority to JP2003572955A priority patent/JP2005526054A/en
Priority to EP03708334A priority patent/EP1483239A2/en
Priority to AU2003212515A priority patent/AU2003212515A1/en
Publication of WO2003074485A2 publication Critical patent/WO2003074485A2/en
Publication of WO2003074485A3 publication Critical patent/WO2003074485A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to heterocychc amide derivatives, pharmaceutically acceptable salts and in vivo hydrolysable esters thereof.
  • These heterocychc amide possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity and thus are potentially useful in methods of treatment of a warm-blooded animal such as man.
  • the invention also relates to processes for the manufacture of said heterocychc amide derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments to inhibit glycogen phosphorylase activity in a warm-blooded animal such as man.
  • the liver is the major organ regulating glycaemia in the post-absorptive state. Additionally, although having a smaller role in the contribution to post-prandial blood glucose levels, the response of the liver to exogenous sources of plasma glucose is key to an ability to maintain euglycaemia.
  • An increased hepatic glucose output (HGO) is considered to play an important role in maintaining the elevated fasting plasma glucose (FPG) levels seen in type 2 diabetics; particularly those with a FPG >140mg/dl (7.8mM).
  • Liver glycogen phosphorylase a activity is elevated in diabetic animal models including the db/db mouse and the fa/fa rat (Aiston S et al (2000). Diabetalogia 43, 589-597). Inhibition of hepatic glycogen phosphorylase with chloroindole inhibitors (CP91149 and CP320626) has been shown to reduce both glucagon stimulated glycogenolysis and glucose output in hepatocytes (Hoover et al (1998) J Med Chem 41, 2934-8; Martin et al (1998) PNAS 95, 1776-81). Additionally, plasma glucose concentration is reduced, in a dose related manner, db/db and ob/ob mice following treatment with these compounds.
  • Bay K 3401 Studies in conscious dogs with glucagon challenge in the absence and presence of another glycogen phosphorylase inhibitor, Bay K 3401, also show the potential utility of such agents where there is elevated circulating levels of glucagon, as in both Type 1 and Type 2 diabetes. In the presence of Bay R 3401, hepatic glucose output and arterial plasma glucose following a glucagon challenge were reduced significantly (Shiota et al, (1997), Am J Physiol, 273: E868).
  • heterocychc amides of the present invention possess glycogen phosphorylase inhibitory activity and accordingly are expected to be of use in the treatment of type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia and obesity, particularly type 2 diabetes.
  • R .1 i s independently selected from C 1-6 alkyl, C 5-7 cycloalkyl, C 5-7 cycloalkylC ⁇ -3 alkyl, C 1-6 alkoxy, Cs -7 cycloalkoxy, C 5- cycloalkylC 1-3 alkoxy, heterocyclyl, heterocyclylC 1-3 alkyl, heterocyclyloxy or heterocyclylC 1-3 alkoxy (wherein each of these groups is substituted on carbon by 1, 2 or 3 hydroxy groups, provided that there is no more than one hydroxy group on the same carbon atom and a ring carbon atom adjacent to a ring heteroatom is not substituted by a hydroxy group) and groups of the formula A or A' :
  • esters for carboxy include C 1-6 alkoxymethyl esters for example methoxymethyl, C 1-6 alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C 3 . 8 cycloalkoxycarbonyloxyC 1-6 alkyl esters for example 1-cyclohexylcarbonyloxyethyl; l,3-dioxolen-2-onylmethyl esters for example 5-methyl-l,3-dioxolen-2-onylmethyl; and C 1-6 alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.
  • n is 1 or 2. In another aspect of the invention m is 1.
  • R is selected from phenyl, pyridyl, oxadiazolyl, oxazolyl, thiazolyl and thienyl (each of which group is optionally substituted by 1 or 2 substituents independently selected from halo, cyano, trifluoromethyl, carbamoyl, N-C 1-3 alkylcarbamoyl, sulfamoyl and N-C 1-3 alkylsulfamoyl); m is 1; and
  • the compounds defined in the present invention possesses glycogen phosphorylase inhibitory activity. This property may be assessed, for example, using the procedure set out below. Assay
  • the reaction is in 50mM HEPES (N-(2-Hydroxyethyl)piperazine-N-(2- ethanesulfonic acid);4-(2-Hydroxyethyl)piperazine-l-ethanesulfonic acid), 2.5mM MgCl 2 , 2.25mM ethylene glycol-bis(b-aminoethyl ether) N,N,N',N'-tetraacetic acid, lOOmM KC1, 2mM D-(+)-glucose pH7.2, containing 0.5mM dithiothreitol, the assay buffer solution, with O.lmg type HI glycogen, 0.15ug glycogen phosphorylase a (GPa) from rabbit muscle and 0.5mM glucose- 1 -phosphate.
  • HEPES N-(2-Hydroxyethyl)piperazine-N-(2- ethanesulfonic acid);4-(2-Hy
  • GP is pre-incubated in the assay buffer solution with the type HI glycogen at 2.5 mg ml "1 for 30 minutes. 40 ⁇ l of the enzyme solution is added to 25 ⁇ l assay buffer solution and the reaction started with the addition of 25 ⁇ l 2mM glucose- 1 -phosphate.
  • Compounds to be tested are prepared in lO ⁇ l 10% DMSO in assay buffer solution, with final concentration of 1% DMSO in the assay.
  • the assay is performed at a test concentration of inhibitor of lO ⁇ M or lOO ⁇ M.
  • Compounds demonstrating significant inhibition at one or both of these concentrations may be further evaluated using a range of test concentrations of inhibitor to determine an IC 50 , a concentration predicted to inhibit the enzyme reaction by 50%.
  • OD620 optical density at 620nM.
  • Typical IC 50 values for compounds of the invention when tested in the above assay are in the range lOO ⁇ M to InM.
  • the activity of the compounds is alternatively determined by measuring the inhibitory effect of the compounds on glycogen degradation, the production of glucose- 1 -phosphate from glycogen is monitored by the multienzyme coupled assay, as described in EP 0 846 464 A2, general method of Pesce et al ( Pesce, M A, Bodourian, S H, Harris, R C, and Nicholson, J F (1977) Clinical Chemistry 23, 1171 - 1717).
  • the reactions were in 384well microplate format in a volume of 50 ⁇ l.
  • the change in fluorescence due to the conversion of the co-factor NAD to NADH is measured at 340nM excitation, 465nm emission in a Tecan Ultra Multifunctional Microplate Reader.
  • the reaction is in 50mM HEPES, 3.5mM KH 2 PO 4 , 2.5mM MgCl 2 , 2.5mM ethylene glycol-bis(b-aminoethyl ether) N,N,N',N'-tetraacetic acid, lOOmM KC1, 8mM D-(+)-glucose pH7.2, containing 0.5mM dithiothreitol, the assay buffer solution.
  • Human recombinant liver glycogen phosphorylase a (hrl GP ⁇ ) 20nM is pre-incubated in assay buffer solution with 6.25mM NAD, 1.25mg type IJJ glycogen at 1.25 mg ml "1 the reagent buffer, for 30 minutes.
  • Typical IC 50 values for compounds of the invention when tested in the above assay are in the range lOO ⁇ M to InM.
  • Example 1 gave an IC 50 value of 0.55 ⁇ m.
  • Rat hepatocytes were isolated by the collagenase perfusion technique, general method of Seglen (P.O. Seglen, Methods Cell Biology (1976) 13 29-83). Cells were cultured on Nunclon six well culture plates in DMEM (Dulbeco's Modified Eagle's Medium) with high level of glucose containing 10% foetal calf serum, NEAA (non essential amino acids), Glutamine, penicillin /streptomycin ((100units/100ug)/ml) for 4 to 6 hours.
  • DMEM Dynamic fetal
  • NEAA non essential amino acids
  • Glutamine penicillin /streptomycin
  • the hepatocytes were then cultured in the DMEM solution without foetal calf serum and with lOnM insulin and lOnM dexamethasone. Experiments were initiated after 18-20 hours culture by washing the cells and adding Krebs-Henseleit bicarbonate buffer containing 2.5mM CaCl 2 and 1% gelatin. The test compound was added and 5 minutes later the cells were challenged with 25nM glucagon. The Krebs-Henseleit solution was removed after 60 min incubation at 37°C , 95%O 2 /5%CO 2 and the glucose concentration of the Krebs-Henseleit solution measured.
  • a pharmaceutical composition which comprises a compound of the formula (1), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.
  • compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).
  • oral use for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixir
  • phosphate or kaolin or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin).
  • the oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents may be added to provide a palatable oral preparation.
  • These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives.
  • compositions of the invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these.
  • Suitable emulsifying agents may be, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening, flavouring and preservative agents.
  • Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.
  • the pharmaceutical compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above.
  • a sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol.
  • Compositions for administration by inhalation may be in the form of a conventional pressurised aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets.
  • Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.
  • the amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration.
  • a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.
  • Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient.
  • the compound of formula (1) will normally be administered to a warm-blooded animal at a unit dose within the range 5-5000 mg per square meter body area of the animal, i.e. approximately 0.1-100 mg/kg, and this normally provides a therapeutically-effective dose.
  • a unit dose form such as a tablet or capsule will usually contain, for example 1-250 mg of active ingredient.
  • Preferably a daily dose in the range of 1-50 mg/kg is employed.
  • the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.
  • glycogen phosphorylase activity described herein may be applied as a sole therapy or may involve, in addition to the subject of the present invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. Simultaneous treatment may be in a single tablet or in separate tablets.
  • simultaneous treatment may be in a single tablet or in separate tablets.
  • diabetes mellitus chemotherapy may include the following main categories of treatment:
  • Insulin sensitising agents including PPARg agonists (for example pioglitazone and rosiglitazone);
  • Haemostasis modulators such as, antithrombotics, activators of fibrinolysis and antiplatelet agents; thrombin antagonists; factor Xa inhibitors; factor Vila inhibitors); antiplatelet agents (eg. aspirin, clopidogrel); anticoagulants (heparin and Low molecular weight analogues, hiradin) and warfarin; and
  • Anti-inflammatory agents such as non-steroidal anti-inflammatory drags (eg. aspirin) and steroidal anti-inflammatory agents (eg. cortisone).
  • a compound of the formula (1) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore, for use as a medicament.
  • a compound of the formula (1) for use as a medicament in the treatment of type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity in a warm-blooded animal such as man.
  • a compound of the formula (1) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore in the manufacture of a medicament for use in the treatment of type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity in a warm-blooded animal such as man.
  • a method of producing a glycogen phosphorylase inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1).
  • a method of treating type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity which comprises administering to said animal an effective amount of a compound of formula (1).
  • a method of treating type 2 diabetes in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1).
  • the size of the dose required for the therapeutic or prophylactic treatment of a particular cell-proliferation disease will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated.
  • a unit dose in the range, for example, 1-100 mg/kg, preferably 1-50 mg/kg is envisaged.
  • the compounds of formula (1) and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardisation of in vitro and in vivo test systems for the evaluation of the effects of inhibitors of cell cycle activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
  • temperatures are given in degrees Celsius (°C); operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18-25°C and under an atmosphere of an inert gas such as argon;
  • organic solutions were dried over anhydrous magnesium sulphate; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 Pascals; 4.5-30 mmHg) with a bath temperature of up to 60°C;
  • NMR data is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300 MHz using perdeuterio dimethyl sulphoxide (DMSO- ⁇ 6 ) as solvent unless otherwise indicated, other solvents (where indicated in the text) include deuterated chloroform CDC1 3 ;
  • DMTMM 4-(4,6-dimethoxy- 1 ,3 ,5-triazin-2-yl)-4-methylmorpholinium chloride THF tetrahydrofuran;

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Heterocyclic amides of formula (1) (A chemical formula should be inserted here - please see paper copy enclosed herewith) (1) wherein: R1 is independently selected from, for example, C1-6alkyl, C5-7cycloalkyl, C5-7cycloalkylC1-3alkyl, C 1-6alkoxy, C5-7cycloalkoxy, C5-7cycloalkylC1-3alkoxy, heterocyclyl, heterocyclylC1-3alkyl, heterocyclyloxy or heterocyclylC1-3alkoxy;R2 is phenyl or heteroaryl; R3 is independently selected from hydrogen, halo, nitro, cyano, hydroxy, carboxy, carbamoyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, fluoromethyl, difluoromethyl, trifluoromethyl and trifluoromethoxy; or a pharmaceutically acceptable salt or pro-drug thereof; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are described.

Description

CHEMICAL COMPOUNDS
The present invention relates to heterocychc amide derivatives, pharmaceutically acceptable salts and in vivo hydrolysable esters thereof. These heterocychc amide possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity and thus are potentially useful in methods of treatment of a warm-blooded animal such as man. The invention also relates to processes for the manufacture of said heterocychc amide derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments to inhibit glycogen phosphorylase activity in a warm-blooded animal such as man.
The liver is the major organ regulating glycaemia in the post-absorptive state. Additionally, although having a smaller role in the contribution to post-prandial blood glucose levels, the response of the liver to exogenous sources of plasma glucose is key to an ability to maintain euglycaemia. An increased hepatic glucose output (HGO) is considered to play an important role in maintaining the elevated fasting plasma glucose (FPG) levels seen in type 2 diabetics; particularly those with a FPG >140mg/dl (7.8mM). (Weyer et al, (1999), J Clin Invest 104: 787-794; Clore & Blackgard (1994), Diabetes 43: 256-262; De Fronzo, R. A., et al, (1992) Diabetes Care 15; 318 - 355; Reaven, G.M. (1995) Diabetologia 38; 3-13). Since current oral, anti-diabetic therapies fail to bring FPG levels to within the normal, non-diabetic range and since raised FPG (and glycHbAlc) levels are risk factors for both macro- (Charles, M.A. et al (1996) Lancet 348, 1657-1658; Coutinho, M. et al (1999) Diabetes Care 22; 233-240; Shaw, J.E. et al (2000) Diabetes Care 23, 34-39) and micro-vascular disease (DCCT Research Group (1993) New. Eng. J. Med. 329; 977-986); the reduction and normalisation of elevated FPG levels remains a treatment goal in type 2 DM. It has been estimated that, after an overnight fast, 74% of HGO was derived from glycogenolysis with the remainder derived from gluconeogenic precursors (Hellerstein et al (1997) Am J Physiol, 272: E163). Glycogen phosphorylase is a key enzyme in the generation by glycogenolysis of glucose- 1 -phosphate, and hence glucose in liver and also in other tissues such as muscle and neuronal tissue.
Liver glycogen phosphorylase a activity is elevated in diabetic animal models including the db/db mouse and the fa/fa rat (Aiston S et al (2000). Diabetalogia 43, 589-597). Inhibition of hepatic glycogen phosphorylase with chloroindole inhibitors (CP91149 and CP320626) has been shown to reduce both glucagon stimulated glycogenolysis and glucose output in hepatocytes (Hoover et al (1998) J Med Chem 41, 2934-8; Martin et al (1998) PNAS 95, 1776-81). Additionally, plasma glucose concentration is reduced, in a dose related manner, db/db and ob/ob mice following treatment with these compounds.
Studies in conscious dogs with glucagon challenge in the absence and presence of another glycogen phosphorylase inhibitor, Bay K 3401, also show the potential utility of such agents where there is elevated circulating levels of glucagon, as in both Type 1 and Type 2 diabetes. In the presence of Bay R 3401, hepatic glucose output and arterial plasma glucose following a glucagon challenge were reduced significantly (Shiota et al, (1997), Am J Physiol, 273: E868).
The heterocychc amides of the present invention possess glycogen phosphorylase inhibitory activity and accordingly are expected to be of use in the treatment of type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia and obesity, particularly type 2 diabetes.
According to one aspect of the present invention there is provided a compound of formula (1):
Figure imgf000003_0001
(1) wherein:
R .1 i,s independently selected from C1-6alkyl, C5-7cycloalkyl, C5-7cycloalkylCι-3alkyl, C1-6alkoxy, Cs-7cycloalkoxy, C5- cycloalkylC1-3alkoxy, heterocyclyl, heterocyclylC1-3alkyl, heterocyclyloxy or heterocyclylC1-3alkoxy (wherein each of these groups is substituted on carbon by 1, 2 or 3 hydroxy groups, provided that there is no more than one hydroxy group on the same carbon atom and a ring carbon atom adjacent to a ring heteroatom is not substituted by a hydroxy group) and groups of the formula A or A' :
Figure imgf000004_0001
(A) (A') wherein x is 0 or 1, r is 0, 1, 2 or 3, s is 1 or 2 and u is 1 or 2; provided that in (A) the hydroxy group is not a substituent on the ring carbon adjacent to the ring oxygen; R2 is phenyl or heteroaryl (each of which is optionally substituted by 1 or 2 substituents independently selected from halo, cyano, trifluoromethyl, difluoromethyl, fluoromethyl, Cι-3alkoxy, C1-3alkanoyl, carbamoyl, N-C1-3alkylcarbamoyl, N,N-di-C1-3alkylcarbamoyl, sulfamoyl, N-C1-3alkylsulfamoyl, N,N-di-C1-3alkylsulfamoyl and groups of the formulae B and B':
Figure imgf000004_0002
(B) (B') wherein x is 0 or 1, r is 0, 1, 2 or 3, s is 1 or 2 and u is 1 or 2; provided that the hydroxy group is not a substituent on the ring carbon adjacent to the ring oxygen); m is 0, 1 or 2; R is independently selected from hydrogen, halo, nitro, cyano, hydroxy, carboxy, carbamoyl,
C1-4alkyl, C2- alkenyl, C2.4alkynyl, C1-4alkoxy, C1-4alkanoyl, fluoromethyl, difluoromethyl, trifluoromethyl and trifluoromethoxy; provided that when R1 is of the formula A or A' then R2 does not contain a group of the formula B or B' and when R2 is of the formula B or B' then R1 does not contain a group of the formula A or A' ; or a pharmaceutically acceptable salt or prodrug thereof.
According to another aspect of the present invention there is provided a compound of formula (1):
Figure imgf000005_0001
(1) wherein:
R is C1-6alkyl, C5-7cycloalkyl, C5-7cycloalkylC1-3alkyl, C1-6alkoxy, C5-7cycloalkoxy, C5-7cycloalkylC1-3alkoxy, heterocyclyl, heterocyclylC1-3alkyl, heterocyclyloxy or heterocyclylC1-3alkoxy (wherein each of these groups is substituted on carbon by 1, 2 or 3 hydroxy groups, provided that there is no more than one hydroxy group on the same carbon atom and a ring carbon atom adjacent to a ring heteroatom is not substituted by a hydroxy group) or R1 is of the formula A or A' : "(CH2)r
Figure imgf000005_0002
(A) -CH2CH(OH)(CH2)uCO2H (A5) wherein x is 0 or 1, r is 0, 1, 2 or 3 and s is 1 or 2; provided that the hydroxy group is not a substituent on the ring carbon adjacent to the ring oxygen;
R is phenyl or heteroaryl (each of which is optionally substituted by 1 or 2 substituents independently selected from halo, cyano, trifluoromethyl, difluoromethyl, fluoromethyl, C . 3alkoxy, C1-3alkanoyl, carbamoyl, N-C1-3alkylcarbamoyl, N,N-di-C1-3alkylcarbamoyl, sulfamoyl, N-C1-3alkylsulfamoyl, N,N-di-C1-3alkylsulfamoyl and groups of the formulae B and
B':
-(CH2)t
Figure imgf000005_0003
(B) -CH2CH(OH)(CH2)uCO2H (B') wherein y is 0 or 1, t is 0, 1, 2 or 3 and u is 1 or 2; provided that the hydroxy group is not a substituent on the ring carbon adjacent to the ring oxygen); m is 0, 1 or 2;
R is independently selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, N-C1-4alkylcarbamoyl, N,N-di-(C1- alkyl)carbamoyl, sulphamoyl, N- . alkylsulphamoyl, N,N-di(C1- alkyl)sulphamoyl, sulfino, sulfo, C1-4alkyl, C2-4alkenyl, C2- 4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1- alkyl)amino, N,N-di-(Cι. 4alkyl)amino, hydroxyC1-4alkyl, fluoromethyl, difluoromethyl, trifluoromethyl and trifluoromethoxy ; provided that when R1 is of the formula A or A' then R2 does not contain a group of the formula B or B' and when R2 is of the formula B or B' then R1 does not contain a group of the formula A or A'; or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof.
In another aspect, the invention relates to compounds of formula (1) as hereinabove defined or to a pharmaceutically acceptable salt.
In another aspect, the invention relates to compounds of formula (1) as hereinabove defined or to a pro-drug thereof. Suitable examples of pro-drugs of compounds of formula (1) are in- vivo hydrolysable esters of compounds of formula (1). Therefore in another aspect, the invention relates to compounds of formula (1) as hereinabove defined or to an in- vivo hydrolysable ester thereof.
It is to be understood that, insofar as certain of the compounds of formula (1) defined above may exist in optically active or racemic forms by virtue of one or more asymmetric carbon atoms, the invention includes in its definition any such optically active or racemic form which possesses glycogen phosphorylase inhibition activity. The synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis from optically active starting materials or by resolution of a racemic form. Similarly, the above-mentioned activity may be evaluated using the standard laboratory techniques referred to hereinafter. Within the present invention it is to be understood that a compound of the formula (1) or a salt thereof may exhibit the phenomenon of tautomerism and that the formulae drawings within this specification can represent only one of the possible tautomeric forms. It is to be understood that the invention encompasses any tautomeric form, which has glycogen phosphorylase inhibition activity and is not to be limited merely to any one tautomeric form utilised within the formulae drawings. The formulae drawings within this specification can represent only one of the possible tautomeric forms and it is to be understood that the specification encompasses all possible tautomeric forms of the compounds drawn not just those forms which it has been possible to show graphically herein.
It is also to be understood that certain compounds of the formula (1) and salts thereof can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which have glycogen phosphorylase inhibition activity.
It is also to be understood that certain compounds of the formula (1) may exhibit polymorphism, and that the invention encompasses all such forms which possess glycogen phosphorylase inhibition activity.
The present invention relates to the compounds of formula (1) as hereinbefore defined as well as to the salts thereof. Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula (1) and their pharmaceutically acceptable salts. Pharmaceutically acceptable salts of the invention may, for example, include acid addition salts of the compounds of formula (1) as hereinbefore defined which are sufficiently basic to form such salts. Such acid addition salts include for example salts with inorganic or organic acids affording pharmaceutically acceptable anions such as with hydrogen halides (especially hydrochloric or hydrobromic acid of which hydrochloric acid is particularly preferred) or with sulphuric or phosphoric acid, or with trifluoroacetic, citric or maleic acid. Suitable salts include hydrochlorides, hydrobromides, phosphates, sulphates, hydrogen sulphates, alkylsulphonates, arylsulphonates, acetates, benzoates, citrates, maleates, fumarates, succinates, lactates and tartrates. In addition where the compounds of formula (1) are sufficiently acidic, pharmaceutically acceptable salts may be formed with an inorganic or organic base which affords a pharmaceutically acceptable cation. Such salts with inorganic or organic bases include for example an alkali metal salt, such as a sodium or potassium salt, an alkaline earth metal salt such as a calcium or magnesium salt, an ammonium salt or for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
The compounds of the invention may be administered in the form of a pro-drag which is broken down in the human or animal body to give a compound of the invention. A prodrag may be used to alter or improve the physical and/or pharmacokinetic profile of the parent compound and can be formed when the parent compound contains a suitable group or substituent which can be derivatised to form a prodrug. Examples of pro-drugs include in- vivo hydrolysable esters of a compound of the invention or a pharmaceutically-acceptable salt thereof.
Various forms of prodrugs are known in the art, for examples see: a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et al. (Academic Press, 1985); b) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and
H. Bundgaard, Chapter 5 "Design and Application of Prodrugs", by H. Bundgaard p. 113-191 (1991); c) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992); d) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77, 285 (1988); and e) N. Kakeya, et al, Chem Pharm Bull, 32, 692 (1984).
An in vivo hydrolysable ester of a compound of formula (1) containing carboxy or hydroxy group is, for example. A pharmaceutically acceptable ester which is cleaved in the human or animal body to produce the parent acid or alcohol.
Suitable pharmaceutically acceptable esters for carboxy include C1-6alkoxymethyl esters for example methoxymethyl, C1-6alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C3.8cycloalkoxycarbonyloxyC1-6alkyl esters for example 1-cyclohexylcarbonyloxyethyl; l,3-dioxolen-2-onylmethyl esters for example 5-methyl-l,3-dioxolen-2-onylmethyl; and C1-6alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.
Suitable pharmaceutically-acceptable esters for hydroxy include inorganic esters such as phosphate esters (including phosphoramidic cyclic esters) and α-acyloxyalkyl ethers and related compounds which as a result of the in-vivo hydrolysis of the ester breakdown to give the parent hydroxy group/s. Examples of -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxymethoxy. A selection of in-vivo hydrolysable ester forming groups for hydroxy include Ci-^alkanoyl, for example acetyl; benzoyl; phenylacetyl; substituted benzoyl and phenylacetyl, Cι.-10alkoxycarbonyl (to give alkyl carbonate esters), for example ethoxycarbonyl; di-(Cι.-4)alkylcarbamoyl and N-(di-(C1-4)alkylaminoethyl)-N-
Figure imgf000008_0001
(to give carbamates); di-(C1-4)alkylaminoacetyl and carboxyacetyl. Examples of ring substituents on phenylacetyl and benzoyl include aminomethyl, (C\. )alkylaminomethyl and di-((C1-4)alkyl)aminomethyl, and morpholino or piperazino linked from a ring nitrogen atom via a methylene linking group to the 3- or 4- position of the benzoyl ring. Other interesting in-vivo hyrolysable esters include, for example, RAC(O)O(C1-6)alkyl- CO-, wherein RA is for example, benzyloxy-(Cr )alkyl, or phenyl). Suitable substituents on a phenyl group in such esters include, for example, 4-(C1-4)piperazino-(C1-4)alkyl, piperazino- (Ci-4)alkyl and morpholino-^ C^alkyl.
In this specification the generic term "alkyl" includes both straight-chain and branched-chain alkyl groups. However references to individual alkyl groups such as "propyl" are specific for the straight chain version only and references to individual branched-chain alkyl groups. For example, "Ci-ealkyl" and "C1-4alkyl" include propyl, isopropyl and t-butyl. An analogous convention applies to other generic terms, for example "hydroxyC1-4alkyl" includes 2-hydroxyethyl, 1-hydroxyethyl and hydroxymethyl. The term "halo" refers to fluoro, chloro, bromo and iodo.
A "heterocychc group" is an optionally substituted saturated, monocyclic ring containing 5-7 ring atoms of which at least 1, 2 or 3 ring atoms are chosen from nitrogen, sulphur or oxygen, and which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH2- group can optionally be replaced by a -C(O)-and a ring sulphur atom may be optionally oxidised to form the S-oxide(s). Examples and suitable values of the term "heterocychc group" are morpholino, 1,3-dioxolanyl, morpholinyl, piperidino and piperidyl. A particular example of a "heterocychc group" is morpholinyl.
Suitable optional substituents for "heterocyclyl" as a saturated or partially saturated ring are 1, 2 or 3 substituents independently selected from halo, cyano, hydroxy, C1-4alkyl, Ci. alkoxy and C1-4alkylS(O)b (wherein b is 0, 1 or 2). Further suitable substituents for "heterocyclyl" as a saturated or partially saturated ring are 1, 2 or 3 substituents independently selected from fluoro, chloro, cyano, hydroxy, methyl, ethyl, methoxy, methylthio, methylsulfinyl and methylsulfonyl.
Suitable optional susbtituents for "heterocyclyl" as an unsaturated ring are 1, 2 or 3 substituents independently selected from halo, cyano, nitro, arnino, hydroxy, C1-4alkyl, . 4alkoxy, C1- alkylS(O)b (wherein b is 0, 1 or 2), N-(C1- alkyl)amino and N,N-(C1-4alkyl)2amino. Further suitable optional susbtituents for "heterocyclyl" as an unsaturated ring are 1, 2 or 3 substituents independently selected from fluoro, chloro, cyano, nitro, amino, methylamino, dimethylamino, hydroxy, methyl, ethyl, methoxy, methylthio, methylsulfinyl and methylsulfonyl.
A heteroaryl group is an aryl monocyclic ring system containing 5 to 7 ring atoms of which 1, 2, 3 or 4 (in particular 1, 2 or 3) ring atoms are chosen from nitrogen, sulphur or oxygen, and which may, unless otherwise specified, be carbon or nitrogen linked. Particular heteroaryl rings are pyridyl, oxadiazolyl, oxazolyl, thiazolyl, thienyl, pyrimidyl, thiadiazolyl, isothiadiazolyl and isoxazolyl.
Suitable optional susbtituents for "heteroaryl" are, unless otherwise stated, 1, 2 or 3 substituents independently selected from halo, cyano, nitro, amino, hydroxy, C1-4alkyl, d_ 4alkoxy, C1-4alkylS(O)b (wherein b is 0, 1 or 2), N-(C1-4alkyl)amino and
N,N-(C1-4alkyl)2amino. Further suitable optional susbtituents for "heterocyclyl" as an unsaturated ring are 1, 2 or 3 substituents independently selected from fluoro, chloro, cyano, nitro, amino, methylamino, dimethylamino, hydroxy, methyl, ethyl, methoxy, methylthio, methylsulfinyl and methylsulfonyl. Examples of "(heterocyclyl)C1-4alkyl" are morpholinomethyl, morpholinethyl, morpholinylmethyl, morpholinylethyl, piperidinomethyl, piperidinoethyl, piperidylmethyl, piperidylethyl, imidazolylmethyl, imidazolylethyl, oxazolylmethyl, oxazolylethyl, 1,3,4- oxadiazolylmethyl, 1,2,4-oxadiazolylmethyl, 1,2,4-oxadiazolylethyl, pyridylmethyl, pyridylethyl, furylmethyl, furylethyl, (thienyl)methyl, (thienyl)ethyl, pyrazinylmethyl, pyrazinylethyl, piperazinylmethyl and piperazinylethyl.
Examples of "aryl" are optionally substituted phenyl and naphthyl.
Examples of "aryl(C1-4)alkyl" are benzyl, phenethyl, naphthylmethyl and naphthylethyl.
Suitable optional substituents for "aryl" groups are, unless otherwise stated, 1, 2 or 3 substituents independently selected from halo, cyano, nitro, amino, hydroxy, C1-4alkyl, C\. alkoxy, C1-4alkylS(O)b (wherein b is 0, 1 or 2), N-(C1-4alkyl)amino and N,N-(C1-4alkyl)2amino. Further suitable optional susbtituents for "aryl" groups are 1, 2 or 3 substituents independently selected from fluoro, chloro, cyano, nitro, amino, methylamino, dimethylamino, hydroxy, methyl, ethyl, methoxy, methylthio, methylsulfinyl and methylsulfonyl.
Where optional substituents are chosen from "0, 1, 2 or 3" groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups. An analogous convention applies to substituents chose from "0, 1 or 2" groups and "1 or 2" groups.
There following are particular and suitable values for certain substituents and groups referred to in this specification. These values may be used where appropriate with any of the definitions and embodiments disclosed hereinbefore, or hereinafter. For the avoidance of doubt each stated species represents a particular and independent aspect of this invention.
Examples of "C1-6alkyl" and "C1- alkyl" include methyl, ethyl and propyl.
Examples of "hydroxyC1-4alkyl" include hydroxymethyl, 2-hydroxyethyl and 2- hydroxypropyl.
Examples of "C1-6alkoxy" and "C1- alkoxy" include methoxy, ethoxy and propoxy.
Examples of "C1-3alkanoyl" and "C1-4alkanoyl" include acetyl and propionyl.
Examples of "N-(C1-6alkyl)sulphamoyl" are N-(methyl)sulphamoyl and N-(ethyl)sulphamoyl.
Examples of "N, N-di-(C1-6alkyl)sulphamoyl" are N,N-(dimethyl)sulphamoyl and N-(methyl)-N-(ethyl)sulphamoyl.
Examples of "N-(C1-6alkyl)carbamoyl" are N-(Cι-4alkyl)carbamoyl, methylaminocarbonyl and ethylaminocarbonyl .
Examples of "N,N-di-(C1-6alkyl)carbamoyl" are N,N-(C1- alkyl)carbamoyl, dimethylaminocarbonyl and methylethylaminocarbonyl. Examples of "C1-4alkanoyloxy" include acetyloxy and propionyloxy.
Examples of "C2-4alkenyl" include vinyl, allyl and 1-propenyl.
Examples of "C -4alkynyl" include ethynyl and 1-propynyl.
Examples of "N-(C1-4alkyl)amino" are methylamino and ethylamino.
Examples of "N,N-di-(C1-4alkyl)amino" are dimethylamino and methylethylamino. Examples of "C5-7cycloalkyl ring" are cyclopentyl and cyclohexyl.
Examples of "dihaloC1-4alkyl" are difluoromethyl and dichloromethyl.
Example of "trihaloC1-4alkyl" is trifluoromethyl.
The term "sulfo" means HOSO2- . The term "sulfino" means HO2S- . Particular values of R1, R2, R3 and m are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.
In one embodiment of the invention are provided compounds of formula (1), in an alternative embodiment are provided pharmaceutically-acceptable salts of compounds of formula (1), in a further alternative embodiment are provided in-vivo hydrolysable esters of compounds of formula (1), and in a further alternative embodiment are provided pharmaceutically-acceptable salts of in-vivo hydrolysable esters of compounds of formula (1). In one aspect R1 is C1-6alkyl, C5-7cycloalkyl, C5-7cycloalkylmethyl, Cι-6alkoxy, C5-
7cycloalkoxy, Cs-7cycloalkylC1-3methoxy, heterocyclyl, heterocyclylmethyl, heterocyclyloxy or heterocyclylmethoxy (each group is substituted by 1 or 2 hydroxy groups provided that there is no more than one hydroxy group on the same carbon atom) or R is of the formula A or A' as hereinabove defined. In another aspect R1 is C1-6alkyl, C5-7cycloalkyl, C5-7cycloalkylmethyl, C1-6alkoxy, C5-
7cycloalkoxy, C5-7cycloalkylC1-3methoxy, heterocyclyl, heterocyclylmethyl, heterocyclyloxy or heterocyclylmethoxy (each group is substituted by 1 or 2 hydroxy groups provided that there is no more than one hydroxy group on the same carbon atom).
In another aspect R1 is C1-6alkyl, C5-7cycloalkyl, C5-7cycloalkylmethyl, C1-6alkoxy, C5- 7cycloalkoxy or C5-7cycloalkylC1-3methoxy, (each group is substituted by 1 or 2 hydroxy groups provided that there is no more than one hydroxy group on the same carbon atom).
In yet another aspect, R1 is ethyl, propyl, cyclopentyl, cyclohexyl, cyclopentylmethyl or cyclohexylmethyl (wherein each group is substituted by 1 or 2 hydroxy groups provided that there is no more than one hydroxy group on the same carbon atom). In yet another aspect, R1 is 2-hydroxyethyl, 2,3-dihydroxypropyl, 3,4- dihydroxycyclopentyl or 3,4-dihydroxycyclopentylmethyl.
In one aspect , R2 is heteroaryl.
Particular heteroaryl rings are pyridyl, oxadiazolyl, oxazolyl, thiazolyl, thienyl, pyrimidyl, thiadiazolyl, isothiadiazolyl and isoxazolyl. More particular heteroaryl rings are pyridyl, oxadiazolyl, oxazolyl, thiazolyl and thienyl.
In another aspect, R2 is phenyl.
In one aspect the phenyl or heteroaryl group in R2 is optionally substituted by 1 or 2 substituents independently selected from halo, cyano, trifluoromethyl, carbamoyl, N-C1-3alkylcarbamoyl, N,N-di-C1-3alkylcarbamoyl, sulfamoyl, N-C1-3alkylsulfamoyl, N,N-di-C1-3alkylsulfamoyl , a group of the formula B and a group of the formula B' as hereinabove defined. In another aspect the phenyl or heteroaryl group in R2 is optionally substituted by 1 or 2 substituents independently selected from halo, cyano, trifluoromethyl, carbamoyl, N- . 3alkylcarbamoyl, N,N-di-C1-3alkylcarbamoyl, sulfamoyl, N-C1-3alkylsulfamoyl, N.N-di-Q. 3alkylsulfamoyl. In another aspect, the phenyl or heteroaryl group in R2 is optionally substituted by 1 or
2 substituents independently selected from halo, cyano, trifluoromethyl, carbamoyl, N-C1-3alkylcarbamoyl, sulfamoyl and N-C1-3alkylsulfamoyl.
In yet another aspect, the phenyl or heteroaryl group in R2 is optionally substituted by
1 or 2 substituents independently selected from fluoro, chloro, cyano, trifluoromethyl, carbamoyl and sulfamoyl.
In yet another aspect, the phenyl or heteroaryl group in R2 is unsubstituted or substituted by 1 fluoro substituent.
In yet another aspect, the phenyl or heteroaryl group in R is unsubstituted.
In one aspect of the present invention m is 1 or 2. In another aspect of the invention m is 1.
In yet another aspect m is 0.
In one aspect of the present invention R3 is selected from hydrogen, halo, cyano, hydroxy, fluoromethyl, difluoromethyl and trifluoromethyl.
In another aspect of the invention R is hydrogen or halo. Preferably R3 is selected from hydrogen, chloro or bromo.
More preferably R3 is chloro.
In another aspect, the invention relates to a class of compounds of the formula (1) wherein:
R1 is selected from C1-6alkyl, Cs-7cycloalkyl, C5-7cycloalkylmethyl, C1-6alkoxy, C5-7cycloalkoxy, C5-7cycloalkylC1-3methoxy, heterocyclyl, heterocyclylmethyl, heterocyclyloxy and heterocyclylmethoxy (wherein each of these groups is substituted by 1 or
2 hydroxy groups provided that there is no more than one hydroxy group on the same carbon atom) or R is of the formula A or A' as hereinabove defined;
R2 is a phenyl or heteroaryl group (each of which is optionally substituted by 1 or 2 substituents independently selected from halo, cyano, trifluoromethyl, carbamoyl, N-C1-3alkylcarbamoyl, N,N-di-C1-3alkylcarbamoyl, sulfamoyl, N-C1-3alkylsulfamoyl, N,N-di-C1-3alkylsulfamoyl, a group of the formula B and a group of the formula B' as hereinabove defined); and m and R are as hereinabove defined; provided that when R1 is of the formula A or A' then R2 does not contain a group of the formula B or B' and when R2 is of the formula B or B' then R1 does not contain a group of the formula A or A'; or a pharmaceutically-acceptable salt or in-vivo hydrolysable ester thereof.
In yet another aspect, the invention relates to a class of compounds of the formula (1) wherein: R1 is selected from C1-6alkyl, C5-7cycloalkyl, C5-7cycloalkylmethyl, C1-6alkoxy, C5-
7cycloalkoxy and C5-7cycloalkylC1-3methoxy, (each group is substituted by 1 or 2 hydroxy groups provided that there is no more than one hydroxy group on the same carbon atom);
R2 is a phenyl or heteroaryl group (each of which is optionally substituted by 1 or 2 substituents independently selected from halo, cyano, trifluoromethyl, carbamoyl, N-C1-3alkylcarbamoyl, N,N-di-C1-3alkylcarbamoyl, sulfamoyl, N-C1-3alkylsulfamoyl and
N,N-di-C1-3alkylsulfamoyl); and m and R3 are as hereinabove defined; or a pharmaceutically-acceptable salt or in-vivo hydrolysable ester thereof.
In yet another aspect, the invention relates to a class of compounds of the formula (1) wherein:
R1 is selected from C1-6alkyl, C5-7cycloalkyl, C5-7cycloalkylmethyl, C1-6alkoxy,
C5-7cycloalkoxy and C5-7cycloalkylC1-3methoxy, (each group is substituted by 1 or 2 hydroxy groups provided that there is no more than one hydroxy group on the same carbon atom);
R2 is a phenyl or heteroaryl group (each of which is optionally substituted by 1 or 2 substituents independently selected from halo, cyano, trifluoromethyl, carbamoyl,
N-C1-3alkylcarbamoyl, N,N-di-C1-3alkylcarbamoyl, sulfamoyl, N-C1-3alkylsulfamoyl and N,N- di-C1-3alkylsulfamoyl); m is as hereinabove defined; and
R is selected from hydrogen, halo, cyano, hydroxy, fluoromethyl, difluoromethyl and trifluoromethyl; or a pharmaceutically-acceptable salt or in-vivo hydrolysable ester thereof. In yet another aspect, the invention relates to a class of compounds of the formula (1) wherein:
R1 is selected from C1-6alkyl, C5-7cycloalkyl, C5-7cycloalkylmethyl, C1-6alkoxy,
C5-7cycloalkoxy and Cs-7cycloalkylC1- methoxy, (each group is substituted by 1 or 2 hydroxy groups provided that there is no more than one hydroxy group on the same carbon atom);
R2 is selected from phenyl, pyridyl, oxadiazolyl, oxazolyl, thiazolyl and thienyl (each of which is optionally substituted by 1 or 2 substituents independently selected from halo, cyano, trifluoromethyl, carbamoyl, N-C1-3alkylcarbamoyl, sulfamoyl, N-C1-3alkylsulfamoyl and
N,N-di-C1-3alkylsulfamoyl); m is 1 or 2; and
R3 is selected from hydrogen, halo, cyano, hydroxy, fluoromethyl, difluoromethyl and trifluoromethyl; or a pharmaceutically-acceptable salt or in-vivo hydrolysable ester thereof.
In yet another aspect, the invention relates to a class of compounds of the formula (1) wherein:
R1 is selected from ethyl, propyl, cyclopentyl, cyclohexyl, cyclopentylmethyl and cyclohexylmethyl (wherein each group is substituted by 1 or 2 hydroxy groups provided that there is no more than one hydroxy group on the same carbon atom);
R is selected from phenyl, pyridyl, oxadiazolyl, oxazolyl, thiazolyl and thienyl (each of which group is optionally substituted by 1 or 2 substituents independently selected from halo, cyano, trifluoromethyl, carbamoyl, N-C1-3alkylcarbamoyl, sulfamoyl and N-C1-3alkylsulfamoyl); m is 1; and
R is chloro; or a pharmaceutically-acceptable salt or in-vivo hydrolysable ester thereof. In yet another aspect, the invention relates to a class of compounds of the formula (1) wherein:
R is selected from 2-hydroxyethyl, 2,3-dihydroxypropyl, 3,4-dihydroxycyclopentyl and 3,4- dihydroxycyclopentylmethyl;
R is phenyl optionally substituted by 1 or 2 substituents independently selected from halo, cyano, trifluoromethyl, carbamoyl, N-C1-3alkylcarbamoyl, sulfamoyl and
N-C i -3 alkylsulf amoyl ; m is 1 or 2; and R is hydrogen or halo; or a pharmaceutically-acceptable salt or in-vivo hydrolysable ester thereof.
A particular compound of the present invention is: 5-chloro-N-{2-[(2-hydroxyethyl)phenylamino]-2-oxoethyl}-lH-indole-2-carboxamide; and pharmaceutically-acceptable salts thereof.
Process for Preparing a Compound of Formula (1)
Another aspect of the present invention provides a process for preparing a compound of formula (1) or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof which process comprises: a) reacting an acid of the formula (2):
(2) or an activated derivative thereof; with an amine of formula (3): ΗΝR'R2 or b) reacting an acid of the formula (4):
Figure imgf000016_0002
(4) or an activated derivative thereof; with an amine of formula (5): HJNTCHzCONR'R2 : wherein R1, R2, R3 and m are, unless otherwise specified, as defined in formula (1); wherein any functional groups are optionally protected; and thereafter if necessary: i) converting a compound of the formula (1) into another compound of the formula (1); ii) removing any protecting groups; iii) forming a pharmaceutically acceptable salt or in vivo hydrolysable ester. Specific reaction conditions for the above reaction are as follows.
Processes a) and b) Acids of formula (2) and amines of formula (3) and acids of formula (4) and amines of formula (5) may be coupled together in the presence of a suitable coupling reagent. Standard peptide coupling reagents known in the art can be employed as suitable coupling reagents, or for example 4-(4,6-dimethoxy-l,3,5-triazin-2-yι)-4- methylmorpholinium chloride, carbonyldiimidazole, l-ethyl-3-(3- dimethylaminopropyl)carbodi-imide hydrochloride and dicyclohexyl-carbodiimide, optionally in the presence of a catalyst such as 1-hydroxybenzotriazole, dimethylaminopyridine or 4-pyrrolidinopyridine, optionally in the presence of a base for example triethylamine, di- isopropylethylamine, pyridine, or 2,6-di-αZ£y/-pyridines such as 2,6-lutidine or 2,6-di-tert-butylpyridine. Suitable solvents include dimethylacetamide, dichloromethane, benzene, tetrahydrofuran and dimethylformamide. The coupling reaction may conveniently be performed at a temperature in the range of -40 to 40°C.
Suitable activated acid derivatives include acid halides, for example acid chlorides, and active esters, for example pentafluorophenyl esters. The reaction of these types of compounds with amines is well known in the art, for example they may be reacted in the presence of a base, such as those described above, and in a suitable solvent, such as those described above. The reaction may conveniently be performed at a temperature in the range of -40 to 40°C.
The acids of formula (2) are commercially available or they are know compounds or they are prepared by processes known in the art. For example, an acid of the formula (2) can be formed by reacting together a compound of the formula (4) and an compound of the formula PO2CCH2NH2 wherein P is a carboxy-protecting group under conditions described above for amide formation and subsequently removing the protecting group. The acids of formula (2) are commercially available or they are know compounds or they are prepared by processes known in the art. Compounds of formulae (3) and (5) may be prepared by reacting an amine of formula
P'HNR1', P'HNR2 , P^NCH^ONHR1 or P'P"NCH2CONHR2 as appropriate with R*-L or R -L, as appropriate, wherein P' and P" are amino protecting groups and L is a suitable leaving group (for example chloro, bromo or iodo) in the presence of a base such as sodium hydride in a suitable solvent. It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogen group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.
It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard practice [for illustration see "Protective Groups in Organic Chemistry", edited by J.W.F.McOmie, Plenum Press (1973), and "Protective groups in Organic Synthesis", 2nd edition, T.W Greene & P. G. M. Wutz, Wiley-Interscience (1991)]. Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.
A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a t-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.
A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon. The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.
Certain intermediates in the preparation of a compound of the formula (1) are novel and form another aspect of the invention.
As stated hereinbefore the compounds defined in the present invention possesses glycogen phosphorylase inhibitory activity. This property may be assessed, for example, using the procedure set out below. Assay
The activity of the compounds is determined by measuring the inhibitory effect of the compounds in the direction of glycogen synthesis, the conversion of glucose- 1 -phosphate into glycogen with the release of inorganic phosphate, as described in EP 0 846 464 A2. The reactions were in 96well microplate format in a volume of lOOμl. The change in optical density due to inorganic phosphate formation was measured at 620nM in a Labsystems iEMS Reader MF by the general method of (Nordlie R.C and Arion WJ, Methods of Enzymology, 1966, 619-625). The reaction is in 50mM HEPES (N-(2-Hydroxyethyl)piperazine-N-(2- ethanesulfonic acid);4-(2-Hydroxyethyl)piperazine-l-ethanesulfonic acid), 2.5mM MgCl2, 2.25mM ethylene glycol-bis(b-aminoethyl ether) N,N,N',N'-tetraacetic acid, lOOmM KC1, 2mM D-(+)-glucose pH7.2, containing 0.5mM dithiothreitol, the assay buffer solution, with O.lmg type HI glycogen, 0.15ug glycogen phosphorylase a (GPa) from rabbit muscle and 0.5mM glucose- 1 -phosphate. GP is pre-incubated in the assay buffer solution with the type HI glycogen at 2.5 mg ml"1 for 30 minutes. 40μl of the enzyme solution is added to 25μl assay buffer solution and the reaction started with the addition of 25μl 2mM glucose- 1 -phosphate. Compounds to be tested are prepared in lOμl 10% DMSO in assay buffer solution, with final concentration of 1% DMSO in the assay. The non-inhibited activity of GPα is measured in the presence of lOμl 10% DMSO in assay buffer solution and maximum inhibition measured in the presence of 30μM CP320626 (Hoover et al (1998) J Med Chem, 41, 2934-8; Martin et al (1998) PΝAS 95, 1776-81). The reaction is stopped after 30min with the addition of 50μl acidic ammonium molybdate solution, 12ug ml"1 in 3.48% H2SO4 with 1% sodium lauryl sulphate and lOug ml"1 ascorbic acid. After 30 minutes at room temperature the absorbency at 620nm is measured.
The assay is performed at a test concentration of inhibitor of lOμM or lOOμM. Compounds demonstrating significant inhibition at one or both of these concentrations may be further evaluated using a range of test concentrations of inhibitor to determine an IC50, a concentration predicted to inhibit the enzyme reaction by 50%.
Activity is calculated as follows:- % inhibition = (1 - (compound OD620 - fully inhibited OD620)/ (non-inhibited rate OD620 - fully inhibited OD620)) * 100. OD620 = optical density at 620nM.
Typical IC50 values for compounds of the invention when tested in the above assay are in the range lOOμM to InM.
The activity of the compounds is alternatively determined by measuring the inhibitory effect of the compounds on glycogen degradation, the production of glucose- 1 -phosphate from glycogen is monitored by the multienzyme coupled assay, as described in EP 0 846 464 A2, general method of Pesce et al ( Pesce, M A, Bodourian, S H, Harris, R C, and Nicholson, J F (1977) Clinical Chemistry 23, 1171 - 1717). The reactions were in 384well microplate format in a volume of 50μl. The change in fluorescence due to the conversion of the co-factor NAD to NADH is measured at 340nM excitation, 465nm emission in a Tecan Ultra Multifunctional Microplate Reader. The reaction is in 50mM HEPES, 3.5mM KH2PO4, 2.5mM MgCl2, 2.5mM ethylene glycol-bis(b-aminoethyl ether) N,N,N',N'-tetraacetic acid, lOOmM KC1, 8mM D-(+)-glucose pH7.2, containing 0.5mM dithiothreitol, the assay buffer solution. Human recombinant liver glycogen phosphorylase a (hrl GPα) 20nM is pre-incubated in assay buffer solution with 6.25mM NAD, 1.25mg type IJJ glycogen at 1.25 mg ml"1 the reagent buffer, for 30 minutes. The coupling enzymes, phosphoglucomutase and glucose-6-phosphate dehydrogenase ( Sigma) are prepared in reagent buffer, final concentration 0.25Units per well. 20μl of the hrl GPa solution is added to lOμl compound solution and the reaction started with the addition of 20ul coupling enzyme solution. Compounds to be tested are prepared in lOμl 5% DMSO in assay buffer solution, with final concentration of 1% DMSO in the assay. The non-inhibited activity of GP is measured in the presence of lOμl 5% DMSO in assay buffer solution and maximum inhibition measured in the presence of 5mgs ml"1 N- ethylmaleimide. After 6 hours at 30°C Relative Fluoresence Units (RFUs) are measured at 340nM excitation, 465nm emission .
The assay is performed at a test concentration of inhibitor of lOμM or lOOμM. Compounds demonstrating significant inhibition at one or both of these concentrations may be further evaluated using a range of test concentrations of inhibitor to determine an IC50, a concentration predicted to inhibit the enzyme reaction by 50%. Activity is calculated as follows :- % inhibition = (1 - (compound RFUs - fully inhibited RFUs)/ (non-inhibited rate RFUs - fully inhibited RFUs)) * 100.
Typical IC50 values for compounds of the invention when tested in the above assay are in the range lOOμM to InM. For example, Example 1 gave an IC50 value of 0.55μm.
The inhibitory activity of compounds was further tested in rat primary hepatocytes. Rat hepatocytes were isolated by the collagenase perfusion technique, general method of Seglen (P.O. Seglen, Methods Cell Biology (1976) 13 29-83). Cells were cultured on Nunclon six well culture plates in DMEM (Dulbeco's Modified Eagle's Medium) with high level of glucose containing 10% foetal calf serum, NEAA (non essential amino acids), Glutamine, penicillin /streptomycin ((100units/100ug)/ml) for 4 to 6 hours. The hepatocytes were then cultured in the DMEM solution without foetal calf serum and with lOnM insulin and lOnM dexamethasone. Experiments were initiated after 18-20 hours culture by washing the cells and adding Krebs-Henseleit bicarbonate buffer containing 2.5mM CaCl2 and 1% gelatin. The test compound was added and 5 minutes later the cells were challenged with 25nM glucagon. The Krebs-Henseleit solution was removed after 60 min incubation at 37°C , 95%O2/5%CO2 and the glucose concentration of the Krebs-Henseleit solution measured.
According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (1), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier. The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).
The compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.
Suitable pharmaceutically acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p-hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the gastrointestinal tract, or to improve their stability and/or appearance, in either case, using conventional coating agents and procedures well known in the art.
Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium 03 00936
-22-
phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, anti- oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).
Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin). The oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid. Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavouring and colouring agents, may also be present. The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these. Suitable emulsifying agents may be, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening, flavouring and preservative agents.
Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent. The pharmaceutical compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above. A sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol.
Compositions for administration by inhalation may be in the form of a conventional pressurised aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets. Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.
For further information on formulation the reader is referred to Chapter 25.2 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.
The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition. Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient. For further information on Routes of Administration and Dosage Regimes the reader is referred to Chapter 25.3 in 03 00936
-24-
Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.
The compound of formula (1) will normally be administered to a warm-blooded animal at a unit dose within the range 5-5000 mg per square meter body area of the animal, i.e. approximately 0.1-100 mg/kg, and this normally provides a therapeutically-effective dose. A unit dose form such as a tablet or capsule will usually contain, for example 1-250 mg of active ingredient. Preferably a daily dose in the range of 1-50 mg/kg is employed. However the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.
The inhibition of glycogen phosphorylase activity described herein may be applied as a sole therapy or may involve, in addition to the subject of the present invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. Simultaneous treatment may be in a single tablet or in separate tablets. For example in the treatment of diabetes mellitus chemotherapy may include the following main categories of treatment:
1) Insulin and insulin analogues;
2) Insulin secretagogues including sulphonylureas (for example glibenclamide, glipizide) and prandial glucose regulators (for example repaglinide, nateglinide);
3) Insulin sensitising agents including PPARg agonists (for example pioglitazone and rosiglitazone);
4) Agents that suppress hepatic glucose output (for example metformin).
5) Agents designed to reduce the absorption of glucose from the intestine (for example acarbose);
6) Agents designed to treat the complications of prolonged hyperglycaemia;
7) Anti-obesity agents (for example sibutramine and orlistat);
8) Anti- dyslipidaemia agents such as, HMG-CoA reductase inhibitors (statins, eg pravastatin); PPAR agonists (fibrates, eg gemfibrozil); bile acid sequestrants (cholestyramine); cholesterol absorption inhibitors (plant stands, synthetic inhibitors); bile acid absorption inhibitors (TBATi) and nicotinic acid and analogues (niacin and slow release formulations); 9) Antihypertensive agents such as, β blockers (eg atenolol, inderal); ACE inhibitors (eg lisinopril); Calcium antagonists (eg. nifedipine); Angiotensin receptor antagonists (eg candesartan), antagonists and diuretic agents (eg. furosemide, benzthiazide);
10) Haemostasis modulators such as, antithrombotics, activators of fibrinolysis and antiplatelet agents; thrombin antagonists; factor Xa inhibitors; factor Vila inhibitors); antiplatelet agents (eg. aspirin, clopidogrel); anticoagulants (heparin and Low molecular weight analogues, hiradin) and warfarin; and
11) Anti-inflammatory agents, such as non-steroidal anti-inflammatory drags (eg. aspirin) and steroidal anti-inflammatory agents (eg. cortisone). According to a further aspect of the present invention there is provided a compound of the formula (1), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore, for use in a method of treatment of a warm-blooded animal such as man by therapy.
According to an additional aspect of the invention there is provided a compound of the formula (1), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore, for use as a medicament.
According to an additional aspect of the invention there is provided a compound of the formula (1), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore, for use as a medicament in the treatment of type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity in a warm-blooded animal such as man.
According to this another aspect of the invention there is provided the use of a compound of the formula (1), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore in the manufacture of a medicament for use in the treatment of type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity in a warm-blooded animal such as man.
According to this another aspect of the invention there is provided the use of a compound of the formula (1), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore in the manufacture of a medicament for use in the treatment of type 2 diabetes in a warm-blooded animal such as man.
According to a further feature of this aspect of the invention there is provided a method of producing a glycogen phosphorylase inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1).
According to this further feature of this aspect of the invention there is provided a method of treating type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1).
According to this further feature of this aspect of the invention there is provided a method of treating type 2 diabetes in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1).
As stated above the size of the dose required for the therapeutic or prophylactic treatment of a particular cell-proliferation disease will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated. A unit dose in the range, for example, 1-100 mg/kg, preferably 1-50 mg/kg is envisaged.
In addition to their use in therapeutic medicine, the compounds of formula (1) and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardisation of in vitro and in vivo test systems for the evaluation of the effects of inhibitors of cell cycle activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
In the above other pharmaceutical composition, process, method, use and medicament manufacture features, the alternative and preferred embodiments of the compounds of the invention described herein also apply.
Examples
The invention will now be illustrated by the following non-limiting examples in which, unless stated otherwise:
(i) temperatures are given in degrees Celsius (°C); operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18-25°C and under an atmosphere of an inert gas such as argon; (ii) organic solutions were dried over anhydrous magnesium sulphate; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 Pascals; 4.5-30 mmHg) with a bath temperature of up to 60°C;
(iii) in general, the course of reactions was followed by TLC and reaction times are given for illustration only;
(iv) yields are given for illustration only and are not necessarily those which can be obtained by diligent process development; preparations were repeated if more material was required; (v) where given, NMR data is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300 MHz using perdeuterio dimethyl sulphoxide (DMSO-δ6) as solvent unless otherwise indicated, other solvents (where indicated in the text) include deuterated chloroform CDC13;
(vi) chemical symbols have their usual meanings; SI units and symbols are used; (vii) solvent ratios are given in volume : volume (v/v) terms; (viii) mass spectra (MS) were ran with an electron energy of 70 electron volts in the chemical ionisation (CI) mode using a direct exposure probe; where indicated ionisation was effected by electron impact (El), fast atom bombardment (FAB) or electrospray (ESP); values for m/z are given; generally, only ions which indicate the parent mass are reported and unless otherwise stated the value quoted is (M-H)"; (ix) The following abbreviations are used:
DMTMM 4-(4,6-dimethoxy- 1 ,3 ,5-triazin-2-yl)-4-methylmorpholinium chloride THF tetrahydrofuran;
Example 1
5-Chloro-N-{2-r(2-hvdroxyethyl)phenylamino]-2-oxoethyl|-lH-indole-2-carboxamide
Figure imgf000028_0001
A solution of N-[(5-chloro-lH-indol-2-yl)carbonyl]glycine (Cas Reg No 186429-62-9; Ηulin, Bernard, et al, PCT International Patent Application (1996) WO 9639384; 374 mg , 1.5mmol) and 2-(phenylamino)ethanol (228mg, 1.6mmol) in TΗF (20ml) was stirred at ambient temperature for 30 minutes. 4-(4,6-Dimethoxy-l,3,5-triazin-2-yl)-4- methylmorpholinium chloride (DMTMM) (480mg, l.όmmol) was added and the reaction mixture stirred at ambient temperature overnight, poured into water (15ml) and extracted with ethyl acetate (3x15ml). The organic extracts were combined and washed with IN citric acid solution (15ml), sodium bicarbonate solution (15ml), dried over magnesium sulphate, filtered and concentrated to give the title product (471mg, 86%). 1H NMR 300 MHz: (DMSOα^) 3.45 (q, 2H), 3.71 (m, 4H), 4.65 (m, IH), 7.09 (s, IH), 7.16 (dd, IH), 7.44 (m, 6H), 7.68 (s, IH), 8.57 (t, IH), 11.74 (s, IH); Mass Spectrum: M+Na+ 393.8.

Claims

Claims
1. A compound of formula (1):
Figure imgf000030_0001
(1) wherein:
R1 is independently selected from C1-6alkyl, C5-7cycloalkyl, C5-7cycloalkylC1-3alkyl, C1-6alkoxy, C5-7cycloalkoxy, C5- cycloalkylC1-3alkoxy, heterocyclyl, heterocyclylC1-3alkyl, heterocyclyloxy or heterocyclylC1-3alkoxy (wherein each of these groups is substituted on carbon by 1, 2 or 3 hydroxy groups, provided that there is no more than one hydroxy group on the same carbon atom and a ring carbon atom adjacent to a ring heteroatom is not substituted by a hydroxy group) and groups of the formula A or A' :
Figure imgf000030_0002
(A) (A') wherein x is 0 or 1, r is 0, 1, 2 or 3, s is 1 or 2 and u is 1 or 2; provided that in (A) the hydroxy group is not a substituent on the ring carbon adjacent to the ring oxygen; R is phenyl or heteroaryl (each of which is optionally substituted by 1 or 2 substituents independently selected from halo, cyano, trifluoromethyl, difluoromethyl, fluoromethyl, C1-3alkoxy, C1-3alkanoyl, carbamoyl, N-C1-3alkylcarbamoyl, N,N-di-C1-3alkylcarbamoyl, sulfamoyl, N-C1-3alkylsulfamoyl, N,N-di-C1-3alkylsulfamoyl and groups of the formulae B and
B'
Figure imgf000031_0001
(B) (B') wherein x is 0 or 1, r is 0, 1, 2 or 3, s is 1 or 2 and u is 1 or 2; provided that the hydroxy group is not a substituent on the ring carbon adjacent to the ring oxygen); m is 0, 1 or 2;
R3 is independently selected from hydrogen, halo, nitro, cyano, hydroxy, carboxy, carbamoyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, fluoromethyl, difluoromethyl, trifluoromethyl and trifluoromethoxy; provided that when R1 is of the formula A or A' then R2 does not contain a group of the formula B or B' and when R2 is of the formula B or B' then R1 does not contain a group of the formula A or A'; or a pharmaceutically acceptable salt or prodrag thereof.
2. A compound of the formula (1) as claimed in claim 1, wherein: R1 is selected from C1-6alkyl, C5-7cycloalkyl, C5-7cycloalkylmethyl, C1-6alkoxy, C5-7cycloalkoxy, C5-7cycloalkylC1-3methoxy, heterocyclyl, heterocyclylmethyl, heterocyclyloxy and heterocyclylmethoxy (wherein each of these groups is substituted by 1 or 2 hydroxy groups provided that there is no more than one hydroxy group on the same carbon atom) or R1 is of the formula A or A' ; R2 is a phenyl or heteroaryl group (each of which is optionally substituted by 1 or 2 substituents independently selected from halo, cyano, trifluoromethyl, carbamoyl, N-C1-3alkylcarbamoyl, N,N-di-C1-3alkylcarbamoyl, sulfamoyl, N-C1-3alkylsulfamoyl, N,N-di-C1-3alkylsulfamoyl, a group of the formula B and a group of the formula B'); or a pharmaceutically-acceptable salt or in-vivo hydrolysable ester thereof.
3. A compound of the formula (1) as claimed in claim 1, wherein:
R1 is selected from C1-6alkyl, Cs_7cycloalkyl, C5-7cycloalkylmethyl, C1-6alkoxy, C5- 7cycloalkoxy and C5-7cycloalkylC1-3methoxy, (each group is substituted by 1 or 2 hydroxy groups provided that there is no more than one hydroxy group on the same carbon atom); R2 is a phenyl or heteroaryl group (each of which is optionally substituted by 1 or 2 substituents independently selected from halo, cyano, trifluoromethyl, carbamoyl, N-C1-3alkylcarbamoyl, N,N-di-C1-3alkylcarbamoyl, sulfamoyl, N-C1-3alkylsulfamoyl and N,N-di-C1-3alkylsulfamoyl); or a pharmaceutically-acceptable salt or in-vivo hydrolysable ester thereof.
4. A compound of the formula (1) as claimed in claim 1 ,wherein:
R1 is selected from ethyl, propyl, cyclopentyl, cyclohexyl, cyclopentylmethyl and cyclohexylmethyl (wherein each group is substituted by 1 or 2 hydroxy groups provided that there is no more than one hydroxy group on the same carbon atom); R2 is selected from phenyl, pyridyl, oxadiazolyl, oxazolyl, thiazolyl and thienyl (each of which group is optionally substituted by 1 or 2 substituents independently selected from halo, cyano, trifluoromethyl, carbamoyl, N-C1-3alkylcarbamoyl, sulfamoyl and N-C1-3alkylsulfamoyl); m is 1; and
R3 is chloro; or a pharmaceutically-acceptable salt or in-vivo hydrolysable ester thereof.
5. A compound of the formula (1) as claimed in claim 1 wherein:
R1 is selected from 2-hydroxyethyl, 2,3-dihydroxypropyl, 3,4-dihydroxycyclopentyl and 3,4- dihydroxycyclopentylmethyl ; R2 is phenyl optionally substituted by 1 or 2 substituents independently selected from halo, cyano, trifluoromethyl, carbamoyl, N-C1-3alkylcarbamoyl, sulfamoyl and
N-C1-3alkylsulfamoyl; m is 1 or 2; and
R3 is hydrogen or halo; or a pharmaceutically-acceptable salt or in-vivo hydrolysable ester thereof.
6. A process for preparing a compound of formula (1), as defined in claim 1 or a pharmaceutically-acceptable salt or an in vivo hydrolysable ester thereof which process comprises: a) reacting an acid of the formula (2):
Figure imgf000033_0001
(2) or an activated derivative thereof; with an amine of formula (3): HNR 2 or b) reacting an acid of the formula (4):
Figure imgf000033_0002
(4) or an activated derivative thereof; with an amine of formula (5): HJSTCHaCONR'R2 : wherein R1, R2, R4 and R5 are, unless otherwise specified, as defined in claim 1; wherein any functional groups are optionally protected; and thereafter if necessary: i) converting a compound of the formula (1) into another compound of the formula (1); ii) removing any protecting groups; iii) forming a pharmaceutically acceptable salt or in vivo hydrolysable ester.
7. A pharmaceutical composition comprising a compound of the formula (1) as claimed in any one of claims 1 to 5 or a pharmaceutically-acceptable salt or in vivo hydrolysable ester thereof and a pharmaceutically-acceptable diluent or carrier.
8. A compound of the formula (1) as claimed in any one of claims 1 to 5, or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, for use as a medicament.
9. The use of a compound of the formula (1), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as claimed in any one of claims 1 to 5, in the manufacture of a medicament for use in the treatment of type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity in a warm-blooded animal.
10. A compound of the formula (1), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as claimed in any one of claims 1 to 5, for use as a medicament in the treatment of type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity in a warm-blooded animal such as man.
11. A compound of the formula (1), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as claimed in any one of claims 1 to 5, in the manufacture of a medicament for use in the treatment of type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity in a warm-blooded animal such as man.
12. A method of treating type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1) as claimed in any one of claims 1 to 5.
13. A method of treating type 2 diabetes in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1) as claimed in any one of claims 1 to 5.
PCT/GB2003/000936 2002-03-06 2003-03-04 Indole-amide derivatives and their use as glycogen phosphorylase inhibitors Ceased WO2003074485A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/506,592 US7115648B2 (en) 2002-03-06 2003-03-04 Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
JP2003572955A JP2005526054A (en) 2002-03-06 2003-03-04 Compound
EP03708334A EP1483239A2 (en) 2002-03-06 2003-03-04 Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
AU2003212515A AU2003212515A1 (en) 2002-03-06 2003-03-04 Indole-amide derivatives and their use as glycogen phosphorylase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0205166.2 2002-03-06
GBGB0205166.2A GB0205166D0 (en) 2002-03-06 2002-03-06 Chemical compounds

Publications (2)

Publication Number Publication Date
WO2003074485A2 true WO2003074485A2 (en) 2003-09-12
WO2003074485A3 WO2003074485A3 (en) 2003-12-04

Family

ID=9932330

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/000936 Ceased WO2003074485A2 (en) 2002-03-06 2003-03-04 Indole-amide derivatives and their use as glycogen phosphorylase inhibitors

Country Status (6)

Country Link
US (1) US7115648B2 (en)
EP (1) EP1483239A2 (en)
JP (1) JP2005526054A (en)
AU (1) AU2003212515A1 (en)
GB (1) GB0205166D0 (en)
WO (1) WO2003074485A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122567B2 (en) 2002-03-06 2006-10-17 Astrazeneca Ab Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity
US7129249B2 (en) 2002-03-06 2006-10-31 Astrazeneca Ab Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase
US7138415B2 (en) 2002-03-06 2006-11-21 Astrazeneca Ab Indolamid derivatives which possess glycogenphosphorylase inhibitory activity
US7166636B2 (en) 2002-03-06 2007-01-23 Astrazeneca Ab Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity
US7169927B2 (en) 2002-03-06 2007-01-30 Astrazeneca Ab Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
WO2007128761A2 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Uses of dpp-iv inhibitors
US7307174B2 (en) 2002-10-03 2007-12-11 Astrazeneca Ab Process and intermediates for the preparation of thienopyrrole derivatives
US7411074B2 (en) 2002-10-03 2008-08-12 Astrazeneca Ab Process and intermediates for the preparation of the thienopyrrole derivatives

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE200740C (en)
US3706810A (en) * 1970-09-15 1972-12-19 American Cyanamid Co N-morpholinoalkyl-thieno(3,2-b)pyrrole-5-carboxamides
US4668769A (en) * 1985-08-02 1987-05-26 Hoover Dennis J Oxa- and azahomocyclostatine polypeptides
US4720503A (en) * 1985-08-02 1988-01-19 Merck & Co., Inc. N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors
US4599198A (en) * 1985-08-02 1986-07-08 Pfizer Inc. Intermediates in polypeptide synthesis
FR2601368B1 (en) * 1986-07-08 1989-04-07 Synthelabo NITROFURAN DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION.
DE3629545A1 (en) 1986-08-30 1988-03-10 Bayer Ag DIHYDROPYRIDINE COMPOUNDS, METHOD FOR THEIR PRODUCTION AND THEIR USE
US4751231A (en) * 1987-09-16 1988-06-14 Merck & Co., Inc. Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents
JPH02124756A (en) 1988-07-27 1990-05-14 Suzuki Sangyo Kk Cementing composition
JPH04179949A (en) 1990-11-15 1992-06-26 Fuji Photo Film Co Ltd New dye forming coupler and silver halide color photographic sensitive material using the same
CA2137832C (en) 1992-06-12 2000-09-26 Dennis J. Hoover Inhibitors of angiotensin i chymase(s) including human heart chymase
ES2081747B1 (en) 1993-09-07 1997-01-16 Esteve Labor Dr AMIDES DERIVED FROM TIENOPIRROLES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICINES.
WO1995024391A1 (en) 1994-03-09 1995-09-14 Novo Nordisk A/S Piperidines and pyrrolidines
US5863903A (en) * 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
FR2723739B1 (en) 1994-08-19 1997-02-14 Sanofi Sa GLYCINAMIDE DERIVATIVES, METHODS FOR THEIR PREPARATION AND MEDICINAL PRODUCTS CONTAINING THEM.
DE4445968A1 (en) 1994-12-22 1996-06-27 Bayer Ag Use of new and known sulphonyl guanazine cpds.
CA2224062C (en) 1995-06-06 2001-09-04 Pfizer Limited Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
EP1134213B1 (en) 1995-06-06 2005-11-02 Pfizer Inc. Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides
FI974437A7 (en) 1995-06-06 1997-12-05 Pfizer Substituted N-(indole-2-carbonyl)amides and derivatives as glycogen phosphorylase inhibitors
AU724003B2 (en) 1995-09-08 2000-09-07 Novo Nordisk A/S 2-alkylpyrrolidines
AU2090897A (en) 1996-02-29 1997-09-16 Mikael Bols Hydroxyhexahydropyridazines
EP0914322A1 (en) 1996-05-27 1999-05-12 Fujisawa Pharmaceutical Co., Ltd. New indolyl and benzofuranyl carboxamides as inhibitors of nitric oxide production
US5952322A (en) 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
EP0946587A2 (en) 1996-12-16 1999-10-06 Fujisawa Pharmaceutical Co., Ltd. New amide compounds
WO1998040353A1 (en) 1997-03-07 1998-09-17 Novo Nordisk A/S Novel heterocyclic compounds
IL132170A0 (en) 1997-05-06 2001-03-19 Novo Nordisk As Novel heterocyclic compounds
UA57811C2 (en) 1997-11-21 2003-07-15 Пфайзер Продактс Інк. Compositions including aldose reductase inhibitors and glycogen phosphorylase inhibitors
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
EP0978279A1 (en) 1998-08-07 2000-02-09 Pfizer Products Inc. Inhibitors of human glycogen phosphorylase
JP4865129B2 (en) 1999-01-13 2012-02-01 ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク Novel method for designing protein kinase inhibitors
AU2535700A (en) 1999-02-12 2000-08-29 Novo Nordisk A/S Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation
JP3795305B2 (en) 1999-07-19 2006-07-12 田辺製薬株式会社 Pharmaceutical composition
US6043091A (en) 1999-07-19 2000-03-28 Isis Pharmaceuticals Inc. Antisense modulation of liver glycogen phosphorylase expression
AU7404700A (en) 1999-09-29 2001-04-30 Novo Nordisk A/S Novel aromatic compounds
DE60007592T2 (en) 1999-09-30 2004-09-16 Pfizer Products Inc., Groton Bicyclic pyrrolylamides as glycogen phosphorylase inhibitors
SE9903998D0 (en) 1999-11-03 1999-11-03 Astra Ab New compounds
DE60026348T2 (en) 1999-11-05 2006-10-19 Societe De Conseils De Recherches Et D`Applications Scientifiques (S.C.R.A.S.) Heterocyclic compounds and their use as medicaments
PT1741446E (en) 2000-01-21 2008-05-09 Novartis Pharma Ag Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
CO5271699A1 (en) 2000-01-24 2003-04-30 Pfizer Prod Inc PROCEDURE FOR THE TREATMENT OF CARDIOMIOPATIA USING INHIBITORS OF THE GLUCOGENO FOSFORILASA
US6555569B2 (en) 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AR027656A1 (en) 2000-03-16 2003-04-09 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS OF INHIBITORS OF GLUCOGENO-FOSFORILASA
US20010053791A1 (en) 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
EP1136071A3 (en) 2000-03-22 2003-03-26 Pfizer Products Inc. Use of glycogen phosphorylase inhibitors
PT1145717E (en) 2000-04-13 2004-08-31 Pfizer Prod Inc SYNERGISTIC EFFECT OF GLIBURIDE AND MILRINONE
TR200401029T4 (en) 2000-06-09 2004-06-21 Aventis Pharma Deutschland Gmbh Acylphenyl-urea derivatives, manufacturing methods and their use as pharmaceuticals
US20020028826A1 (en) 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US20020013334A1 (en) 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
IL144507A0 (en) 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
GB0021831D0 (en) * 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
AU2001288110A1 (en) 2000-09-27 2002-04-08 Takeda Chemical Industries Ltd. Spiro compounds
HU227197B1 (en) 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
US6933317B2 (en) 2000-11-01 2005-08-23 Shionogi & Co. Ltd. PGD2 receptor antagonistic pharmaceutical compositions
WO2002080844A2 (en) 2001-04-04 2002-10-17 Genzyme Corporation Novel bgp compounds for therapy and diagnosis and methods for using same
PE20021091A1 (en) 2001-05-25 2003-02-04 Aventis Pharma Gmbh DERIVATIVES OF PHENYLUREA SUBSTITUTED WITH CARBONAMIDE AND PROCEDURE FOR THEIR PREPARATION
US7144863B2 (en) 2001-06-01 2006-12-05 Eli Lilly And Company GLP-1 formulations with protracted time action
CA2465382A1 (en) 2001-10-29 2003-05-08 Japan Tobacco Inc. Indole compound and medicinal use thereof
AU2002352868A1 (en) 2001-11-27 2003-06-10 Merck & Co., Inc. 4-aminoquinoline compounds
MXPA03000966A (en) 2002-02-28 2003-09-04 Pfizer Prod Inc Antidiabetic agents.
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
JPWO2003091213A1 (en) 2002-04-25 2005-09-02 アステラス製薬株式会社 Novel amide derivative or salt thereof
US7057046B2 (en) * 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
GB0222909D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222912D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
WO2004041780A2 (en) 2002-11-07 2004-05-21 Pfizer Products Inc. N-(indole-2-carbonyl) amides as anti-diabetic agents
US7098235B2 (en) * 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
JP2004196702A (en) 2002-12-18 2004-07-15 Yamanouchi Pharmaceut Co Ltd Novel amide derivative or its salt
US7501440B2 (en) * 2003-03-07 2009-03-10 Sanofi-Aventis Deutschland Gmbh Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
BRPI0409465A (en) 2003-04-17 2006-05-02 Pfizer Prod Inc carboxamide derivatives as antidiabetic agents
BRPI0409952A (en) * 2003-04-30 2006-04-25 Pfizer Prod Inc anti-diabetic agents
MXPA05012547A (en) 2003-05-21 2006-05-25 Prosidion Ltd Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase.
WO2004113345A1 (en) 2003-06-20 2004-12-29 Japan Tobacco Inc. Fused pyrrole compound and medicinal use thereof
GB0318464D0 (en) 2003-08-07 2003-09-10 Astrazeneca Ab Chemical compounds
GB0319690D0 (en) 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
GB0319759D0 (en) 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
WO2005020985A1 (en) 2003-08-29 2005-03-10 Astrazeneca Ab Indolamide derivatives which possess glycogen phosphorylase inhibitory activity
WO2005020986A1 (en) 2003-08-29 2005-03-10 Astrazeneca Ab Heterocyclic amide derivatives which posses glycogen phosphorylase inhibitory activity
GB0320422D0 (en) 2003-08-30 2003-10-01 Astrazeneca Ab Chemical compounds

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122567B2 (en) 2002-03-06 2006-10-17 Astrazeneca Ab Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity
US7129249B2 (en) 2002-03-06 2006-10-31 Astrazeneca Ab Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase
US7138415B2 (en) 2002-03-06 2006-11-21 Astrazeneca Ab Indolamid derivatives which possess glycogenphosphorylase inhibitory activity
US7166636B2 (en) 2002-03-06 2007-01-23 Astrazeneca Ab Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity
US7169927B2 (en) 2002-03-06 2007-01-30 Astrazeneca Ab Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
US7332515B2 (en) 2002-03-06 2008-02-19 Astrazeneca Ab Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity
US7307174B2 (en) 2002-10-03 2007-12-11 Astrazeneca Ab Process and intermediates for the preparation of thienopyrrole derivatives
US7411074B2 (en) 2002-10-03 2008-08-12 Astrazeneca Ab Process and intermediates for the preparation of the thienopyrrole derivatives
WO2007128761A2 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Uses of dpp-iv inhibitors
EP2351568A2 (en) 2006-05-04 2011-08-03 Boehringer Ingelheim International GmbH Uses of dpp-iv inhibitors

Also Published As

Publication number Publication date
GB0205166D0 (en) 2002-04-17
JP2005526054A (en) 2005-09-02
WO2003074485A3 (en) 2003-12-04
US7115648B2 (en) 2006-10-03
EP1483239A2 (en) 2004-12-08
AU2003212515A8 (en) 2003-09-16
US20050159472A1 (en) 2005-07-21
AU2003212515A1 (en) 2003-09-16

Similar Documents

Publication Publication Date Title
EP1658069B1 (en) Heterocyclic amide derivatives which possess glycogen phosphorylase inhibitory activity
US7122567B2 (en) Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity
EP1658067B1 (en) Indolamide derivatives which possess glycogen phosphorylase inhibitory activity
US7138415B2 (en) Indolamid derivatives which possess glycogenphosphorylase inhibitory activity
US7169927B2 (en) Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
EP1656136A1 (en) Heterocyclic amide derivatives which possess glycogen phosphorylase inhibitory activity
WO2005020986A1 (en) Heterocyclic amide derivatives which posses glycogen phosphorylase inhibitory activity
US7115648B2 (en) Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
US7332515B2 (en) Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity
WO2005019172A1 (en) Indol-2-amides as glycogen phosphorylase inhibitors
WO2005020985A1 (en) Indolamide derivatives which possess glycogen phosphorylase inhibitory activity
BRPI0606838A2 (en) compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, use of a compound or a pharmaceutically acceptable salt thereof, and process for preparing a compound or a pharmaceutically acceptable salt thereof
HK1089965B (en) Indolamide derivatives which possess glycogen phosphorylase inhibitory activity
HK1090288B (en) Heterocyclic amide derivatives which possess glycogen phosphorylase inhibitory activity
CN101151267A (en) Chemical compounds
CN101151245A (en) Indane amide derivatives with glycogen phosphorylase inhibitory activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003708334

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10506592

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003572955

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003708334

Country of ref document: EP